Promising combo for rare breast cancer subtype hits early snag

NCT ID NCT04504331

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two drugs—infigratinib (a targeted therapy) and tamoxifen (a hormone therapy)—in people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The goal was to find a safe dose. However, the study was terminated early after enrolling only 4 participants, so we have very limited information about how well the combination works or its side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Infigratinib (a targeted drug) combined with tamoxifen (hormone therapy)
What this could lead to
If it worked, this combination might offer a new treatment option for people with a specific genetic subtype of advanced breast cancer.
What could go wrong
This was a very early (Phase 1) trial that was terminated after enrolling only 4 people, so we have very little data on safety or effectiveness. The results may not apply to a broader population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.